Abstracts - PAGE Meeting (Population Approach Group Europe)

Abstracts (24)

I-06

Predictive Model for Identification of Responders/Non Responders in Metastatic Breast Cancer Patients Treated with Docetaxel

Wednesday 10:15-11:45

I-15Brendan Bender

A semi-mechanistic population Pharmacokinetic-Pharmacodynamic (PKPD) model of thrombocytopenia characterizing the effect of trastuzumab-DM1 (T-DM1) on platelet counts in patients with HER2-positive metastatic breast cancer

Wednesday 10:15-11:45

I-21Michael Block

Mechanistic PBPK/PD modeling for prediction of study outcome of cancer therapies: Translating in-vitro information into valid in-vivo predictions

Wednesday 10:15-11:45

I-23Guillaume Bonnefois

A nonlinear mixed effect model to study albumin-mediated drug transport into endothelial cells in vitro.

Wednesday 10:15-11:45

I-24Stephan Borghorst

Age Dependent Volume of Distribution of Pegylated Asparaginase (OncasparTM) in children and adults

Wednesday 10:15-11:45

II-09

Using the Virtual Tumour to predict and optimize drug combination regimens

Wednesday 14:55-16:10

II-14Gregory Ferl

Population analysis of the DCE-MRI response of liver metastases to a single dose of bevacizumab in CRC patients

Wednesday 14:55-16:10

II-16Nicolas Frances

Integrating distribution to tumor tissue into a dynamic PK/PD model to evaluate the anti-cancer effect of erlotinib in patient-derived LXFA 677 tumor xenograft mice

Wednesday 14:55-16:10

II-28Iztok Grabnar

Bayesian Estimation of Methotrexate Pharmacokinetics in Children with Acute Lymphoblastic Leukaemia and Prediction of Folinic Acid Rescue

Wednesday 14:55-16:10

II-31Joachim Grevel

A physiology-based model predicts pharmacokinetics, target occupancy in the tumour, and HSP70 biomarker response in serum for the HSP90 inhibitor, 17-AAG

Wednesday 14:55-16:10

II-36Neeraj Gupta

Population PK and PK/PD Analysis of Intravenous Investigational Agent MLN9708 in Solid Tumors and Lymphoma Patients

Wednesday 14:55-16:10

III-04Steve Kuan

Population Pharmacokinetic Modeling of Investigational Agent MLN4924 in Cancer Patients

Thursday 09:50-11:05

III-17Paolo Magni

A new population PK/PD model to assess the myelotoxicity of candidate drugs in preclinical and in clinical studies

Thursday 09:50-11:05

III-21Maria Matoses Osborne

Ex Vivo modeling of the apoptotic effects of Vivia009 and its metabolite in patients with Chronic Lymphocytic Leukemia

Thursday 09:50-11:05

III-30

Predicting the Gemcitabine efficacy by a stochastic language based model

Thursday 09:50-11:05

III-34Ronald Niebecker

Importance of study design for estimation of Vmax and Km characterising nonlinear monoclonal antibody clearance

Thursday 09:50-11:05

III-37Valerie Nock

Leukopenia following triple high-dose chemotherapy and stem cell rescue

Thursday 09:50-11:05

III-50Kirill Peskov

Systems Modeling of EphB4/ephrinB2 Signaling Pathways

Thursday 09:50-11:05

IV-03Franziska Schädeli Stark

A semi-mechanistic population pharmacokinetic model for trastuzumab emtansine (T-DM1) antibody-drug conjugate and total antibody in patients with metastatic breast cancer (mBC)

Thursday 15:05-16:20

IV-11Alexandre Sostelly

Characterization of the interaction between irinotecan, SN-38 and MBLI-87, a new BCRP inhibitor, with a multi-scale semi-mechanistic PKPD model

Thursday 15:05-16:20

IV-27Mirjam Trame

Busulfan Dosing in Children: Body Weight versus Body Surface Area or Allometric Body Weight Dosing

Thursday 15:05-16:20

IV-50Mélanie Wilbaux

Population K-PD modeling of CA125 and tumor size kinetics in relapsed ovarian cancer patients

Thursday 15:05-16:20

IV-58James Yates

Characterisation of Xenograft Response to Docetaxel by Nonlinear Mixed Effects Modelling

Thursday 15:05-16:20

IV-63Jianping Zhang

Population Pharmacokinetics of Lapatinib in Cancer Patients

Thursday 15:05-16:20